Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis
2025-524362-20-00Phase 2Authorised
- Sponsor
- Freya Biosciences
- Start
- Mar 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of FB301 in bacterial vaginosis (BV) (3 arms), sponsored by Freya Biosciences. Planned start Mar 2026; status: authorised.
02
Drugs
FB301
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on 2025-524362-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524362-20-00.